✦ LIBER ✦

Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris

✍ Scribed by R. Gniadecki; K. Kragballe; T.N. Dam; L. Skov

Book ID: 108671621
Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 175 KB
Volume: 164
Category: Article
ISSN: 0007-0963
DOI: 10.1111/j.1365-2133.2011.10213.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Drug survival rates of biologic treatmen

Drug survival rates of biologic treatments in patients with psoriasis vulgaris

✍ A.M.G. Brunasso; M. Puntoni; C. Massone 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 157 KB

Comparison of effectiveness and safety o

Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs

✍ Mariangela Atteno; Rosario Peluso; Luisa Costa; Stefania Padula; Salvatore Iervo 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 108 KB

Direct comparison of treatment responses

Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry

✍ Merete Lund Hetland; Ib Jarle Christensen; Ulrik Tarp; Lene Dreyer; Annette Hans 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 124 KB 👁 2 views

Comparison of the response to infliximab

Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register

✍ Kimme L. Hyrich; Deborah P. M. Symmons; Kath D. Watson; Alan J. Silman; British 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB 👁 3 views

## Abstract ## Objective To compare outcome at 6 months in unselected “real‐world” patients with rheumatoid arthritis treated with etanercept or infliximab as either monotherapy, cotherapy with methotrexate (MTX), or cotherapy with another disease‐modifying antirheumatic drug (DMARD). ## Methods